Researchers Report Clinical Proof-of-Concept Data for Vivace Therapeutics' VT3989, a First for a Cancer Drug Targeting the Hippo Pathway, in Oral Presentation at AACR 2023
SAN MATEO, Calif., April 16, 2023 /PRNewswire/ -- Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway, today announced that the first clinical data for a cancer treatment targeting the Hippo pathway was presented at the American Association for Cancer Research (AACR) Annual Meeting 2023. Results from the company's Phase 1 clinical study of its first-in-class transcriptional enhanced associate domain (TEAD) autopalmitoylation inhibitor, VT3989, showed the compound to be well tolerated with durable antitumor responses in patients with advanced malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations. These findings were presented by Timothy A. Yap, M.D., Ph.D., of The University of Texas MD Anderson Cancer Center, during an oral plenary session at the conference. The AACR conference is being held April 14-19, 2023, in Orlando, Florida.
- The AACR conference is being held April 14-19, 2023, in Orlando, Florida.
- Tumor response was observed in patients with mesothelioma with and without NF2 mutations and other solid tumors with NF2 mutations.
- Because mesothelioma patients often have NF2 mutations or loss of Merlin it was an a priori indication of interest.
- "Preclinical data suggested that blocking the YAP-TEAD interaction could shrink tumors, and these clinical data validate that approach.